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Abstract. Background/Aim: Phenothiazines constitute a
versatile family of compounds in terms of biological activity,
which have also gained a considerable attention in cancer
research. Materials and Methods: Three phenothiazines
(promethazine, chlorpromazine and thioridazine) have been
tested in combination with 11 active selenocompounds
against MDR (ABCB1-overexpressing) mouse T-lymphoma
cells to investigate their activity as combination
chemotherapy and as antitumor adjuvants in vitro with a
checkerboard combination assay. Results: Seven
selenocompounds showed toxicity on mouse embryonic
fibroblasts, while three showed selectivity towards tumor
cells. Two compounds showed synergism with all tested
phenothiazines in low concentration ranges (1.46-11.25 μM).
Thioridazine was the most potent among the three
phenothiazines. Conclusion: Phenothiazines belonging to
different generations showed different levels of adjuvant
activities. All the tested phenothiazines are already approved
medicines with known pharmacological and toxicity profiles,
therefore, their use as adjuvants in cancer may be considered
as a potential drug repurposing strategy. 
Phenothiazines constitute a versatile family of compounds in
terms of biological activity: though they were widely used,
the interest towards these agents grew tremendously after
promethazine (an antihistaminic agent) and chlorpromazine
(an antipsychotic drug) were discovered in the 1940s (1).
Since then, a wide variety of related compounds have been
discovered and used in psychiatric patients, but recent
studies indicate that these drugs could be also utilized in the
treatment of other disorders, such as neurodegenerative
diseases, tumors, and infections (2). Phenothiazines can
inhibit efflux pumps causing multidrug resistance (MDR)
(3). This inhibition is suggested by the observation that
phenothiazines used as adjuvants in antibiotic therapy can
re-sensitize resistant bacteria to certain antibiotics (3). Other
studies have also shown that phenothiazines have a direct
antibacterial effect, especially against MDR Mycobacterium
tuberculosis infections, which is a pathogen of considerable
morbidity and mortality (4). 
Phenothiazines have also gained considerable attention in
the field of cancer research (5). Their antitumor activity is
exerted through different biological mechanisms, including
the aforementioned MDR efflux pump inhibition (5). Several
in vitro studies show that thioridazine can effectively inhibit
P-glycoprotein (or ABCB1), therefore reversing resistance to
cancer chemotherapy. This inhibition of MDR efflux pumps
enables the reduction of the dosage for chemotherapy drugs
without reducing their therapeutic effect, thus reducing their
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side effects (2, 5). Besides, phenothiazines – especially
thioridazine and trifluoperazine – can exert antitumor activity
due to their capacity to trigger apoptosis through different
mechanisms, e.g., the inhibition of DNA protein kinases and
DNA repair (6, 7), and inhibition of the binding of calcium
to Ca2+-dependent enzymes (8). 
Selenium and selenocompounds (Se-compounds) have
crucial roles in pivotal biological processes, and there is a
growing body of evidence of the potential applications of
organoselenium compounds as potent chemopreventive,
antiproliferative and cytotoxic drugs (9, 10). Moreover, Se-
compounds (Se-compounds) as sodium selenite and
selenocystine have the ability to enhance the anticancer
effects exerted by chemotherapy drugs currently used in
clinical practice, such as cisplatin and doxorubicin,
respectively (11, 12). In line with these findings, our group
synthesized a series of 30 selenoesters and one cyclic
selenoanhydride with marked antiproliferative and/or
cytotoxic activity in selected prostate (PC-3), breast (MCF-
7), lung (A549) and colon (HT-29) cancer cell lines. These
compounds also showed potent chemopreventive activity
(13). In subsequent studies, 10 selenoesters and 1
selenoanhydride of the abovementioned 31 Se-compounds
were selected for performing a more-in-depth evaluation. Our
results showed that they have: (i) a potent cytotoxic activity
(even in submicromolar concentrations) in human colon
adenocarcinoma and breast cancer cell lines, (ii) capacity to
inhibit the ABCB1 efflux pump overexpressed in MDR
sublines of these colon / breast cancer cell lines with higher
potency than known reference inhibitors like verapamil or
thioridazine, and (iii) the ability to trigger apoptosis (14, 15). 
Based on these promising results, in the present study,
three phenothiazines (namely promethazine, chlorpromazine
and thioridazine) were combined with these 11 active Se-
compounds against MDR mouse T-lymphoma cells to
investigate their activity in combination with chemotherapy
and as antitumor adjuvants in vitro. In addition, the toxicity
of the tested compounds and phenothiazines was studied in
non-cancerous NIH/3T3 mouse embryonic fibroblast cells.
Materials and Methods
Cell lines. pHa MDR1/A retrovirus was used to transfect L5178Y
mouse T-cell lymphoma cells (PAR; parental cell line) (ECACC
Cat. No. 87111908, acquired from the Food and Drug
Administration, Silver Spring, MD, USA) as formerly described by
Cornwell et al. (16). The ABCB1-expressing cell line L5178Y
(MDR; multidrug resistant) was selected by culturing the infected
cells with colchicine. The L5178Y human ABCB1-transfected
subline was cultured in McCoy’s 5A medium (Sigma-Aldrich, St
Louis, MO, USA) supplemented with 10% heat-inactivated horse
serum (Sigma-Aldrich), 200 mM L-glutamine (Sigma-Aldrich) and
a penicillin-streptomycin (Sigma-Aldrich) mixture at concentrations
of 100 U/l and 10 mg/l, respectively. 
The NIH/3T3 mouse embryonic fibroblast cell line (ATCC CRL-
1658) was acquired from LGC Promochem, (Teddington, UK). The
cell line was cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM, containing 4.5 g/l glucose) supplemented with 10% heat-
inactivated fetal bovine serum and a penicillin-streptomycin (Sigma-
Aldrich) mixture at concentrations of 100 U/l and 10 mg/l,
respectively. All cell lines were incubated at 37˚C, in a 5% CO2,
95% air atmosphere.
Compounds. Re-synthesis, purification and characterization of
cyclic selenoanhydride (1) and the ten selenoesters 2-11 included
in our study (Figure 1) were performed as described previously
(13). All tested compounds were pure and chemically stable on
air, according to the spectroscopic (IR, MS, 1H- and 13C-NMR)
and the elemental analysis performed to confirm the structures
of the different derivatives as reported previously (13).
Additionally, four reference compounds 12-15 were obtained
from the following providers: potassium selenocyanate (KSeCN)
and phthalic anhydride (15 and 12, respectively; Sigma-Aldrich,
Seelze, Germany), potassium cyanate (KOCN, 13, Chempur,
Piekary Śląskie, Poland), ammonium thiocyanate (NH4SCN, 14,
Polskie Odczynniki Chemiczne, Gliwice, Poland) (Figure 1)
(14). Compounds were dissolved in DMSO to obtain stock
solutions. Working solutions were prepared by dilution in water,
keeping the concentration of DMSO below 1 % in all the
experiments. 
The remaining chemicals used in the study were purchased from
Sigma-Aldrich, (St Louis, MO, USA). These were: promethazine
(PMZ), chlorpromazine (CPZ), thioridazine (TZ), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
sodium dodecyl sulphate (SDS) and dimethyl sulfoxide (DMSO)
(Figure 2). All solutions were prepared on the day of the assay.
Assay for cytotoxic effect. The effects of increasing concentrations
of the phenothiazines alone on cell growth were tested in 96-well
microtiter plates. The parental and multidrug resistant mouse T-
lymphoma cells were cultured using McCoy’s 5A medium
supplemented with 10% heat-inactivated horse serum. The density
of the cells was adjusted to 1×104 cells per well (in 100 μl of
medium per well) and then added to the 96-well flat-bottomed
microtiter plates containing the dilutions of the tested Se-
compounds. The cells were incubated at 37˚C, in a 5% CO2, 95%
air atmosphere. The cytotoxic activity of the Se-compounds was
previously determined on parental and multidrug resistant mouse T-
lymphoma cells (17). 
The adherent mouse embryonic fibroblast cells were cultured in
96-well flat-bottomed microtiter plates in DMEM supplemented
with 10% heat-inactivated fetal bovine serum. The cells were
incubated at 37˚C, in a 5% CO2, 95% air atmosphere. In a separate
plate, the respective dilutions of the tested compounds were
prepared. The density of the cells was adjusted to 1×104 cells per
well and the cells were seeded for 4 h at 37˚C, 5% CO2. Then, the
medium was removed and the cells were incubated with the various
compounds at 37˚C for 24 h. At the end of the incubation period,
20 μl of MTT solution (from a stock solution of 5 mg/mL) were
added to each well. After incubation at 37˚C for 4 h, 100 μl of
sodium dodecyl sulfate (SDS) (Sigma) solution (10% in 0.01 M
HCI) were added to each well and the plates were further incubated
at 37˚C overnight (14, 15,18). Cell growth was determined by
measuring the optical density (OD) at 540/630 nm with Multiscan
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EX ELISA reader (Thermo Labsystems, Cheshire, WA, USA).
Inhibition of the cell growth was determined according to the
formula below:
Checkerboard combination assay. A checkerboard microplate
method was applied to study the effect of drug interactions between
the Se-compounds (1-11), the reference chalcogens (12-15) and the
phenothiazines (PMZ, CPZ and TZ). The assay was carried out
using multidrug-resistant mouse T-lymphoma cells overexpressing
the ABCB1 transporter (15). The dilutions of phenothiazines were
made in the direction from left to right in 100 μl (stock solutions
and final concentrations used in the assay are presented in Table I),
and the dilutions of the Se-compounds from the top to bottom in the
microtiter plate in 50 μl volume. The cells were re-suspended in
culture medium and distributed into each well in 50 μl containing
6×103 cells. The cells were incubated for 72 h. At the end of the
incubation period the cell growth rate was determined by the MTT
assay as described above. The combination index (CI) values at
50% of the growth inhibition dose (ED50) were determined using
CompuSyn software (ComboSyn, Inc., Paramus, NJ, USA) to plot
four to five data points to each ratio (19). CI values were calculated
by means of the median-effect equation, according to the Chou-
Talalay method, where CI<1, CI=1, and CI>1 represent synergism,
additive effect (or no interaction), and antagonism, respectively
(19). 
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Figure 1. Structure of the Se-compounds (1-11), reference chalcogens (12-15) and phenothiazines evaluated in this study. 
Table I. Cytotoxicity of the tested compounds against NIH/3T3 mouse
embryonic fibroblast cells and selectivity indices (SI).
                          NIH/3T3                                             SI
                            A - IC50
                             (μM)                          A/B (31)                    A/C (31)
1                             >100                               ≥25                            ≥22
2                              23.7                               0.24                           0.24
3                             >100                               5.1                             5.9
4                             >100                              ≥1.0                           ≥1.0
5                             >100                              ≥1.0                           ≥1.0
6                              69.7                              ≤0.70                         ≤0.70
7                              23.7                              ≤0.24                         ≤0.24
8                              74.5                              ≤0.75                         ≤0.75
9                              0.62                               0.81                           0.60
10                            1.35                               1.44                           3.14
11                            0.82                               0.63                           0.85
12                           >100                              ≥1.0                           ≥1.0
13                           >100                              ≥1.0                           ≥1.0
14                           >100                              ≥1.0                           ≥1.0
15                           >100                              ≥1.0                           ≥1.0
PMZ: Promethazine; CPZ: chlorpromazine; TZ: thioridazine; B: IC50
of the tested compounds against parental (PAR) mouse T-lymphoma
cells (14); C: IC50 of tested compounds against multidrug resistant
(MDR) mouse T-lymphoma cells (14); SI: Selectivity Index; SI<1
values denote lack of selectivity, 1<SI<3 mean a slight selectivity and
3<SI<6 values indicate moderate selectivity and are signalled with
italics; whereas values of SI<6 indicate that the compounds are strongly
selective and are highlighted in bold (14, 19).
Results
The cytotoxic activity of the Se-compounds and the
reference chalcogens has been previously determined on
parental and multidrug resistant mouse T-lymphoma cells
(17). The final concentration of the Se-compounds used in
the combination experiments was chosen in accordance with
our previous results, while the cytotoxicity of the
phenothiazines was assessed before performing the
checkerboard combination assay to determine their ideal
concentrations for these experiments (the concentrations of
the stock solutions used and the final concentrations are
presented in Table I). Using the NIH/3T3 mouse embryonic
fibroblast cell line, the toxicity on non-tumoral cells and the
selectivity of the Se-compounds and phenothiazines was also
assessed and the results were expressed in terms of the
selectivity index (SI) values (14, 20). Out of the fifteen
tested compounds, seven showed toxicity against the mouse
embryonic fibroblasts (namely compounds 2, 6, 7, 8, 9, 10
and 11) at 100 μM concentrations, while only three showed
selectivity (compound 1: strongly selective, compounds 3
and 10: moderately selective) towards tumor cells, in
agreement with our previous results on murine lymphoma
cell lines (Table II) (14). 
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Figure 2. Interactions of the Se-compounds 1-11 and the reference chalcogens 12-15 with promethazine. The concentration of the tested (O/S/Se)-
compounds are presented below the graph, the concentration of promethazine is given inside graph (in bold: submicromolar concentration, in italics
concentration between 1 and 5 μM, in plain text concentration between 5 and 10 μM, in grey concentration higher than 10 μM).
The results of the combination experiments of Se-
compounds and promethazine, chlorpromazine and
thioridazine are shown in Figures 2, 3 and 4, respectively.
In addition, the concentrations that showed the most
beneficial interactions in these experiments are also
highlighted. As a general rule, compounds 2-5 presented
with the most advantageous interaction profile (i.e. the
highest CI scores were observed). The compounds 2 and 5
showed synergism with all tested phenothiazines). This is
further highlighted by the fact that these compounds showed
synergism with the phenothiazines in low concentration
ranges (1.46-11.25 μM). In contrast, compounds 6-8, and
the reference compounds 12-15 mainly exhibited
antagonism with phenothiazines (Figures 2-4). The
compounds with low IC50 values in the present study and
previous reports (1, 10 and 11) also showed additive or
antagonistic interactions with the phenothiazines, with the
exception of compound 9, presenting synergism with
chlorpromazine and thioridazine (CI values=0.58-0.82).
Comparison of the results between the different
phenothiazines indicated a pronounced tendency for
decrease for the majority of Se-compounds from
promethazine to thioridazine, with CI values going as low
as CI2=0.276 in the case of thioridazine (Figures 2-4).
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Figure 3. Interactions of the Se-compounds 1-11 and the reference chalcogens 12-15 with chlorpromazine. The concentration of the tested (O/S/Se)-
compounds are presented below the graph, the concentration of chlorpromazine is given inside graph (in bold: submicromolar concentration, in
italics concentration between 1 and 5 μM, in plain text concentration between 5 and 10 μM, in grey concentration higher than 10 μM).
Discussion
The diversity of biological activities by phenothiazines and
related compounds has been highlighted by numerous
studies, both in psychopharmacology and in potentially novel
therapeutic indications (1-5). The pleiotropy in their
biological activities has also been shown in the case of their
antipsychotic effects. For instance, they can act as non-
selective antagonists of the dopamine receptor, serotonin
receptors, histamine receptors, α-adrenergic receptors and
acetylcholine receptors (2). Certain phenothiazine
compounds are currently used for the treatment of diseases:
chlorpromazine as an antipsychotic drug (21); promethazine
as antihistaminic; thioridazine as an antipsychotic, antitumor
and antibacterial drug; trifluoperazine as a dopamine
receptor-antagonist and methylene blue as an antioxidant and
as a component of the therapy of cyanide intoxications and
neurodegenerative diseases (1, 2, 21). 
The interest in Se-compounds as anticancer agents and
adjuvants in chemotherapy has increased substantially in the
last 15-20 years (1-7, 22). The activity of the present Se-
compounds in combination with a selection of chemotherapy
drugs has been studied on a MDR mouse T-lymphoma cell
line (23). It was found that the anticancer drugs that
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Figure 4. Interactions of the Se-compounds 1-11 and the reference chalcogens 12-15 with thioridazine. The concentration of the tested (O/S/Se)-
compounds are presented below the graph, the concentration of thioridazine is given inside graph (in bold: submicromolar concentration, in italics
concentration between 1 and 5 μM, in plain text concentration between 5 and 10 μM, in grey concentration higher than 10 μM).
interacted in a more synergistic manner with these Se-
compounds were vincristine, doxorubicin, cyclophosphamide
and methotrexate. In line to the results of this study,
compounds 2-5 were shown to be highly effective adjuvants
in very low concentrations (especially the thiophene-
derivative compound 2, showing strong synergism with all
six tested chemotherapeutic drugs and verapamil). However,
the cyclic selenoanhydride (1) and the methyl-ketone
containing selenoesters (compounds 9-11) interacted
synergistically or antagonistically with the anticancer drugs
and phenothiazine evaluated.
In line with previous studies, the inorganic chalcogen salts
and the O-isoster of compound 1 also showed no synergistic
potential (23). In subsequent experiments in microbial model
systems, it has been suggested that the biological activity of
Se-compounds is dependent on their degradation into
biologically-active species in the presence of oxygen; thus,
their potential as anticancer adjuvants may also be mediated
by a similar, yet unexplained mechanism (24). 
Considering these results, phenothiazines have potential
to be used as adjuvants in cancer chemotherapy. Our results
suggest that phenothiazines with different chemical
modifications showed different levels of adjuvant
properties: thioridazine (a second-generation phenothiazine)
showed lower CI values in a lower concentration range
compared to promethazine and chlorpromazine (first-
generation phenothiazines). However, the presence of the
chlorine atom in position 2 of chlorpromazine was
previously shown to enhance its biological activities,
therefore it is unsurprising that these compounds showed
more potent activity in our assays than the parental
compound phenothiazine (4). The tested phenothiazines are
all already approved medicines with known
pharmacological and toxicity profiles, therefore, their use as
adjuvants in cancer may be considered as a potential drug
repurposing strategy. The synthesis of novel chemical
compounds/libraries with phenothiazine-related structures
and their biological screening as antitumor adjuvants may
lead to potent lead compounds, capable of becoming
relevant molecules for testing in animal experiments and
human clinical trials.
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